by Maria Zannes | Mar 15, 2018 | Press Releases
FEBRUARY 28, 2018 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held cancer diagnostics company, today announced it had been approved for membership in the Early Detection Research Network (EDRN), an initiative of the National Cancer Institute (NCI). EDRN...
by Maria Zannes | Dec 29, 2017 | Events
bioAffinity Technologies’ CEO, Maria Zannes, will present at Biotech Showcase ™ 2018, to be held January 8–10 during the most important week in healthcare at the Hilton San Francisco Union Square. Presentation details are as follows: Date: Tuesday, January 9,...
by Maria Zannes | Dec 29, 2017 | News
DECEMBER 26, 2017 As published in the San Antonio Business Journal By W. Scott Bailey It’s been a landmark year for San Antonio’s biotech industry. Multiple companies have hit major milestones en route to greater international expansion and new product development....
by Maria Zannes | Dec 11, 2017 | News
DECEMBER 8, 2017 As published in the San Antonio Business Journal By W. Scott Bailey In an effort to shore up plans to commercialize its initial product, bioAffinity Technologies is adding more scientific and financial firepower to its arsenal. The San Antonio-based...
by Maria Zannes | Nov 30, 2017 | Press Releases
NOVEMBER 29, 2017 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held cancer diagnostics and therapeutics company, today announced the appointments of Stephen Squinto, Ph.D., and Gary Rubin, CPA, to its Board of Directors. Dr. Squinto is a Venture Partner...
